Company intelligence / Profile preview

Bryn Pharma

Raleigh, North Carolina, United Statesbrynpharma.com ↗

Ownership: Private
Development stage: NDA

Overview

Bryn Pharma has completed clinical trials for its epinephrine nasal spray (NDS1C) showing positive results in pharmacokinetics and safety studies. Recent data showed enhanced absorption of active drug compared to injectable products, with no serious or unexpected adverse events across the clinical development program. A Phase 1 open-label study demonstrated that two doses of 13.2 mg NDS1C given five minutes apart resulted in approximately 50% increase in epinephrine absorption with no notable effect on pharmacodynamics or safety compared to a single dose.

Therapeutic areas: Immunology
Modalities: Small molecules (epinephrine)
Industry: Biotech

Drug pipeline

1 asset

utuly

Beyond the preview

Go deeper on Bryn Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bryn Pharma.

Explore the full profile